The who, what, why, when, how and where of vasospastic angina

Circulation Journal

Volumn 80, Issue 2, 2016, Pages 289-298

  Beltrame, John F ^a   Crea, Filippo ^b   Kaski, Juan Carlos ^c   Ogawa, Hisao ^d   Ong, Peter ^e   Sechtem, Udo ^e   Shimokawa, Hiroaki ^f   Noel Bairey Merz, C ^g  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b CATHOLIC UNIVERSITY   (Italy)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d KUMAMOTO UNIVERSITY   (Japan)

^e ROBERT BOSCH HOSPITAL   (Germany)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Coronary artery disease; Coronary spasm; Ischemic heart disease; Variant angina; Vasospastic angina

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLONIDINE; DILTIAZEM; FASUDIL; GUANETHIDINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEBIVOLOL; NICORANDIL; NITRATE; PIOGLITAZONE; TRIACYLGLYCEROL; VERAPAMIL;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY SPASM; DISEASE REGISTRY; DRUG THERAPY; ELECTROCARDIOGRAPHY; HUMAN; MICROVASCULAR ISCHEMIA; OUT OF HOSPITAL CARDIAC ARREST; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; REVIEW; SMOKING CESSATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VARIANT ANGINA PECTORIS; ANGINA, UNSTABLE; CORONARY VASOSPASM; PATHOPHYSIOLOGY; PROCEDURES;

ANGINA, UNSTABLE; CORONARY VASOSPASM; ELECTROCARDIOGRAPHY; HUMANS;

EID: 84955490907     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-1202     Document Type: Review

References (133)

1. Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. Int J Cardiol 2013; 168: 934-945.
2. Yamanaga K, Tsujita K, Komura N, Kaikita K, Sakamoto K, Miyazaki T, et al. Single-wire pressure and flow velocity measurement for quantifying microvascular dysfunction in patients with coronary vasospastic angina. Am J Physiol Heart Circ Physiol 2015; 308: H478-H484.
3. Radico F, Cicchitti V, Zimarino M, De Caterina R. Angina pectoris and myocardial ischemia in the absence of obstructive coronary artery disease: Practical considerations for diagnostic tests. JACC Cardiovasc Interv 2014; 7: 453-463.
4. Kipling R, Gleeson JM. Just so stories. Doubleday, Lane Cove, 1912; 83.
5. Miller D, Waters DD, Warnica W, Szlachcic J, Kreeft J, Theroux P. Is variant angina the coronary manifestation of a generalized vasospastic disorder? N Engl J Med 1981; 304: 763-766.
6. Nakamura Y, Shinozaki N, Hirasawa M, Kato R, Shiraishi K, Kida H, et al. Prevalence of migraine and Raynaud’s phenomenon in Japanese patients with vasospastic angina. Jpn Circ J 2000; 64: 239-242.
7. Koh KK, Kim SH, Lee KH, Kwon KS, Kim EJ, Baik SH, et al. Does prevalence of migraine and Raynaud’s phenomenon also increase in Korean patients with proven variant angina? Int J Cardiol 1995; 51: 37-46.
8. Di Fiore DP, Zeitz CJ, Arstall MA, Rajendran S, Sheikh AR, Beltrame JF. Clinical determinants of acetylcholine-induced coronary artery spasm in Australian patients. Int J Cardiol 2015; 193: 59-61.
9. Scholl JM, Benacerraf A, Ducimetiere P, Chabas D, Brau J, Chapelle J, et al. Comparison of risk factors in vasospastic angina without significant fixed coronary narrowing to significant fixed coronary narrowing and no vasospastic angina. Am J Cardiol 1986; 57: 199-202.
10. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 1993; 87: 76-79.
11. Takaoka K, Yoshimura M, Ogawa H, Kugiyama K, Nakayama M, Shimasaki Y, et al. Comparison of the risk factors for coronary artery spasm with those for organic stenosis in a Japanese population: Role of cigarette smoking. Int J Cardiol 2000; 72: 121-126.
12. Sato K, Kaikita K, Nakayama N, Horio E, Yoshimura H, Ono T, et al. Coronary vasomotor response to intracoronary acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive patients with coronary spasm: Analysis of a single-center study over 20 years. J Am Heart Assoc 2013; 2: e000227, doi: 10.1161/JAHA.113.000227.
13. Nobuyoshi M, Abe M, Nosaka H, Kimura T, Yokoi H, Hamasaki N, et al. Statistical analysis of clinical risk factors for coronary artery spasm: Identification of the most important determinant. Am Heart J 1992; 124: 32-38.
14. Maouad J, Fernandez F, Hebert JL, Zamani K, Barrillon A, Gay J. Cigarette smoking during coronary angiography: Diffuse or focal narrowing (spasm) of the coronary arteries in 13 patients with angina at rest and normal coronary angiograms. Cathet Cardiovasc Diagn 1986; 12: 366-375.
15. Miwa K, Fujita M, Miyagi Y, Inoue H, Sasayama S. High-density lipoprotein cholesterol level and smoking modify the prognosis of patients with coronary vasospasm. Clin Cardiol 1995; 18: 267-272.
16. Pristipino C, Beltrame JF, Finocchiaro ML, Hattori R, Fujita M, Mongiardo R, et al. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation 2000; 101: 1102-1108.
17. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013): Digest version. Circ J 2014; 78: 2779-2801.
18. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): Digest version. Circ J 2010; 74: 1745-1762.
19. Beltrame JF, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J 2015 August 5, doi:10.1093/eurheartj/ehv351.
20. Prinzmetal M, Kennamer R, Merliss R, Wada T, Bor N. Angina pectoris. I. A variant form of angina pectoris; preliminary report. Am J Med 1959; 27: 375-388.
21. Lanza GA, Sestito A, Sgueglia GA, Infusino F, Manolfi M, Crea F, et al. Current clinical features, diagnostic assessment and prognostic determinants of patients with variant angina. Int J Cardiol 2007; 118: 41-47.
22. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: Differences between Japanese and Caucasian patients. J Am Coll Cardiol 1999; 33: 1442-1452.
23. Ong P, Athanasiadis A, Borgulya G, Voehringer M, Sechtem U. 3-year follow-up of patients with coronary artery spasm as cause of acute coronary syndrome: The CASPAR (coronary artery spasm in patients with acute coronary syndrome) study follow-up. J Am Coll Cardiol 2011; 57: 147-152.
24. Takagi Y, Takahashi J, Yasuda S, Miyata S, Tsunoda R, Ogata Y, et al. Prognostic stratification of patients with vasospastic angina: A comprehensive clinical risk score developed by the Japanese coronary spasm association. J Am Coll Cardiol 2013; 62: 1144-1153.
25. Fukai T, Koyanagi S, Takeshita A. Role of coronary vasospasm in the pathogenesis of myocardial infarction: Study in patients with no significant coronary stenosis. Am Heart J 1993; 126: 1305-1311.
26. Da Costa A, Isaaz K, Faure E, Mourot S, Cerisier A, Lamaud M. Clinical characteristics, aetiological factors and long-term prognosis of myocardial infarction with an absolutely normal coronary angiogram; a 3-year follow-up study of 91 patients. Eur Heart J 2001; 22: 1459-1465.
27. Canavy I, Dutrillat C, Garcia E, Bonnet JL, Bory M. Prospective study on the mechanism of myocardial infarction without significant coronary stenosis. Arch Mal Coeur Vaiss 1999; 92: 225-233 (in French).
28. Nakayama N, Kaikita K, Fukunaga T, Matsuzawa Y, Sato K, Horio E, et al. Clinical features and prognosis of patients with coronary spasm-induced non-ST-segment elevation acute coronary syndrome. J Am Heart Assoc 2014; 3: e000795, doi:10.1161/JAHA.114.000795.
29. Ong P, Athanasiadis A, Hill S, Vogelsberg H, Voehringer M, Sechtem U. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol 2008; 52: 523-527.
30. Igarashi Y, Tamura Y, Tanabe Y, Fujita T, Yamazoe M, Shibata A. Angina-linked syncope and lack of calcium antagonist therapy predict cardiac arrest before definitive diagnosis of vasospastic angina. Coron Artery Dis 1994; 5: 881-887.
31. Igarashi Y, Tamura Y, Suzuki K, Tanabe Y, Yamaguchi T, Fujita T, et al. Coronary artery spasm is a major cause of sudden cardiac arrest in survivors without underlying heart disease. Coron Artery Dis 1993 4: 177-185.
32. Kawana A, Takahashi J, Takagi Y, Yasuda S, Sakata Y, Tsunoda R, et al. Gender differences in the clinical characteristics and outcomes of patients with vasospastic angina: A report from the Japanese Coronary Spasm Association. Circ J 2013; 77: 1267-1274.
33. Yasue H, Takizawa A, Nagao M, Nishida S, Horie M, Kubota J, et al. Long-term prognosis for patients with variant angina and influential factors. Circulation 1988; 78: 1-9.
34. Maseri A, Beltrame JF, Shimokawa H. Role of coronary vasoconstriction in ischemic heart disease and search for novel therapeutic targets. Circ J 2009; 73: 394-403.
35. Bentivoglio L, Gruntzig A. Relief by intracoronary glyceryl trinitrate of coronary artery spasm resistant to sublingual route of administration. Br Heart J 1981; 46: 581-583.
36. Przybojewski J. The importance of excluding coronary artery vasospasm before percutaneous transluminal coronary angioplasty: A case report. S Afr Med J 1986; 70: 495-499.
37. Hanratty CG, Koyama Y, Rasmussen HH, Nelson GI, Hansen PSWard MR. Exaggeration of nonculprit stenosis severity during acute myocardial infarction: Implications for immediate multivessel revascularization. J Am Coll Cardiol 2002; 40: 911-916.
38. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.
39. Robertson RM, Wood AJ, Vaughn WK, Robertson D. Exacerbation of vasotonic angina pectoris by propranolol. Circulation 1982; 65: 281-285.
40. Zaya M, Mehta PK, Bairey Merz CN. Provocative testing for coronary reactivity and spasm. J Am Coll Cardiol 2014; 63: 103-109.
41. Nakao K, Ohgushi M, Yoshimura M, Morooka K, Okumura K, Ogawa H, et al. Hyperventilation as a specific test for diagnosis of coronary artery spasm. Am J Cardiol 1997; 80: 545-549.
42. Song JK, Lee SJ, Kang DH, Cheong SS, Hong MK, Kim JJ, et al. Ergonovine echocardiography as a screening test for diagnosis of vasospastic angina before coronary angiography. J Am Coll Cardiol 1996; 27: 1156-1161.
43. Heupler FA, Proudfit WL, Razavi M, Shirey EK, Greenstreet R, Sheldon WC. Ergonovine maleate provocative test for coronary arterial spasm. Am J Cardiol 1978; 41: 631-640.
44. Okumura K, Yasue H, Matsuyama K, Goto K, Miyagi H, Ogawa H, et al. Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm. J Am Coll Cardiol 1988; 12: 883-888.
45. Curry RC, Pepine CJ, Sabom MB, Conti CR. Similarities of ergonovine-induced and spontaneous attacks of variant angina. Circulation 1979; 59: 307-314.
46. Ozaki Y, Takatsu F, Osugi J, Sugiishi M, Watarai M, Anno T, et al. Long-term study of recurrent vasospastic angina using coronary angiograms during ergonovine provocation tests. Am Heart J 1992; 123: 1191-1198.
47. Shin DI, Baek SH, Her SH, Han SH, Ahn Y, Park KH, et al. The 24-month prognosis of patients with positive or intermediate results in the intracoronary ergonovine provocation test. JACC Cardiovasc Interv 2015; 8: 914-923.
48. Buxton A, Goldberg S, Hirshfeld JW, Wilson J, Mann T, Williams DO, et al. Refractory ergonovine-induced coronary vasospasm: Importance of intracoronary nitroglycerin. Am J Cardiol 1980; 46: 329-334.
49. Ong P, Athanasiadis A, Borgulya G, Vokshi I, Bastiaenen R, Kubik S, et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation 2014; 129: 1723-1730.
50. Takagi Y, Yasuda S, Takahashi J, Tsunoda R, Ogata Y, Seki A, et al. Clinical implications of provocation tests for coronary artery spasm: Safety, arrhythmic complications, and prognostic impact: Multicentre registry study of the Japanese Coronary Spasm Association. Eur Heart J 2013; 34: 258-267.
51. Sueda S, Saeki H, Otani T, Mineoi K, Kondou T, Yano K, et al. Major complications during spasm provocation tests with an intracoronary injection of acetylcholine. Am J Cardiol 2000; 85: 391-394, A310.
52. Wei J, Mehta PK, Johnson BD, Samuels B, Kar S, Anderson RD, et al. Safety of coronary reactivity testing in women with no obstructive coronary artery disease: Results from the NHLBI-sponsored WISE (Women’s Ischemia Syndrome Evaluation) study. JACC Cardiovasc Interv 2012; 5: 646-653.
53. Miwa K, Fujita M, Miyagi Y. Beneficial effects of smoking cessation on the short-term prognosis for variant angina: Validation of the smoking status by urinary cotinine measurements. Int J Cardiol 1994; 44: 151-156.
54. Morikawa Y, Mizuno Y, Harada E, Katoh D, Kashiwagi Y, Morita S, et al. Aerobic interval exercise training in the afternoon reduces attacks of coronary spastic angina in conjunction with improvement in endothelial function, oxidative stress, and inflammation. Coron Artery Dis 2013; 24: 177-182.
55. Yasue H, Mizuno Y, Harada E, Itoh T, Nakagawa H, Nakayama M, et al. Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol 2008; 51: 1742-1748.
56. Johnson S, Mauritson D, Willerson J, Hillis L. A controlled trial of verapamil for Prinzmetal’s variant angina. N Engl J Med 1981; 304: 862-866.
57. Ginsburg R, Lamb I, Schroeder J, Hu M, Harrison D. Randomized double-blind comparison of nifedipine and isosorbide dinitratetherapy in variant angina pectoris due to coronary artery spasm. Am Heart J 1982; 103: 44-49.
58. Antman E, Muller J, Goldberg S, MacAlpin R, Rubenfire M, Tabatznik B, et al. Nifedipine therapy for coronary-artery spasm: Experience in 127 patients. N Engl J Med 1980; 302: 1269-1273.
59. Chahine RA, Feldman RL, Giles TD, Nicod P, Raizner AE, Weiss RJ, et al. Randomised placebo-controlled trial of amlodipine in vasospastic angina. J Am Coll Cardiol 1993; 21: 1365-1370.
60. Goldberg S, Reichek N, Wilson J, Hirshfeld JW, Muller J, Kastor JA. Nifedipine in the treatment of Prinzmetal’s (variant) angina. Am J Cardiol 1979; 44: 804-810.
61. Heupler FJ, Proudfit W. Nifedipine therapy for refractory coronary arterial spasm. Am J Cardiol 1979; 44: 798-803.
62. Higuma T, Oikawa K, Kato T, Mori Y, Kudo T, Yamamoto T, et al. Comparison of the effects of long-acting nifedipine CR and diltiazem R in patients with vasospastic angina: Aomori coronary spastic angina study. J Cardiol 2010; 56: 354-360.
63. Nishigaki K, Inoue Y, Yamanouchi Y, Fukumoto Y, Yasuda S, Sueda S, et al. Prognostic effects of calcium channel blockers in patients with vasospastic angina. Circ J 2010; 74: 1943-1950.
64. Takahashi J, Nihei T, Takagi Y, Miyata S, Odaka Y, Tsunoda R, et al. Prognostic impact of chronic nitrate therapy in patients with vasospastic angina: Multicentre registry study of the Japanese coronary spasm association. Eur Heart J 2015; 36: 228-237.
65. Kosugi M, Nakagomi A, Shibui T, Kato K, Kusama Y, Atarashi H, et al. Effect of long-term nitrate treatment on cardiac events in patients with vasospastic angina. Circ J 2011; 75: 2196-2205.
66. Aizawa T, Ogasawara K, Nakamura F, Hirosaka A, Sakuma T, Nagashima K, et al. Effect of nicorandil on coronary spasm. Am J Cardiol 1989; 63: 75J-79J.
67. Lablanche JM, Bauters C, Leroy F, Bertrand ME. Prevention of coronary spasm by nicorandil: Comparison with nifedipine. J Cardiovasc Pharmacol 1992; 20: 82-85.
68. Kishida H, Murao S. Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris. Clin Pharmacol Ther 1987; 42: 166-174.
69. Shimokawa H. 2014 Williams Harvey Lecture: Importance of coronary vasomotion abnormalities-from bench to bedside. Eur Heart J 2014; 35: 3180-3193.
70. Nihei T, Takahashi J, Tsuburaya R, Ito Y, Shiroto T, Hao K, et al. Circadian variation of Rho-kinase activity in circulating leukocytes of patients with vasospastic angina. Circ J 2014; 78: 1183-1190.
71. Inokuchi K, Ito A, Fukumoto Y, Matoba T, Shiose A, Nishida T, et al. Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J Cardiovasc Pharmacol 2004; 44: 275-277.
72. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rhokinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002; 105: 1545-1547.
73. Shin ES, Lee JH, Yoo SY, Park Y, Hong YJ, Kim MH, et al. A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina. Heart 2014; 100: 1531-1536.
74. Morita S, Mizuno Y, Harada E, Kashiwagi Y, Yoshimura M, Murohara T, et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, suppresses coronary spasm. Coron Artery Dis 2014; 25: 671-677.
75. Miyagi H, Yasue H, Okumura K, Ogawa H, Goto K, Oshima S. Effect of magnesium on anginal attack induced by hyperventilation in patients with variant angina. Circulation 1989; 79: 597-602.
76. Kawano H, Motoyama T, Hirai N, Kugiyama K, Ogawa H, Yasue H. Estradiol supplementation suppresses hyperventilation-induced attacks in postmenopausal women with variant angina. J Am Coll Cardiol 2001; 37: 735-740.
77. Kugiyama K, Motoyama T, Hirashima O, Ohgushi M, Soejima H, Misumi K, et al. Vitamin C attenuates abnormal vasomotor reactivity in spasm coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol 1998; 32: 103-109.
78. Kern MJ, Ganz P, Horowitz JD, Gaspar J, Barry WH, Lorell BH, et al. Potentiation of coronary vasoconstriction by beta-adrenergic blockade in patients with coronary artery disease. Circulation 1983; 67: 1178-1185.
79. Ito A, Fukumoto Y, Shimokawa H. Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers. J Cardiovasc Pharmacol 2004; 44: 480-485.
80. Akkus NI, Rajpal S, Peter E. Resolution of nebivolol-induced coronary vasospasm by intracoronary nitroglycerin during a coronary angiogram. Rev Port Cardiol 2012; 31: 825-828.
81. Koh K, Roe I, Lee M, Cho S, Kim S. Variant angina complicatingergot therapy of migraine. Chest 1994; 105: 1259-1260.
82. Santoro F, Spennati G, Ieva R, De Gennaro L, Correale M, Lopizzo A, et al. Late onset of coronary vasospasm after administration of methyl-ergometrine for gynecologic bleeding. Int J Cardiol 2012; 161: 29-30.
83. Janjua M, Badshah A, Allen SA. Images in cardiology. Epinephrine- induced ST elevation: A case of endobronchial topical epinephrine- induced coronary vasospasm. Heart 2009; 95: 656.
84. Karch SB. Coronary artery spasm induced by intravenous epinephrine overdose. Am J Emerg Med 1989; 7: 485-488.
85. Yildirim AB, Basarici I, Kucuk M. Recurrent ventricular arrhythmias and myocardial infarctions associated with cocaine induced reversible coronary vasospasm. Cardiol J 2010; 17: 512-517.
86. Mueller L, Gallagher RM, Ciervo CA. Vasospasm-induced myocardial infarction with sumatriptan. Headache 1996; 36: 329-331.
87. Chalaupka FD. Acute myocardial infarction with sumatriptan: A case report and review of the literature. Headache 2009; 49: 762-764.
88. Shimizu M, Hata K, Takaoka H, Kanazawa K, Shinke T, Matsumoto H, et al. Sumatriptan provokes coronary artery spasm in patients with variant angina: Possible involvement of serotonin 1B receptor. Int J Cardiol 2007; 114: 188-194.
89. Willett F, Curzen N, Adams J, Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan. Br Med J 1992; 304: 1415.
90. Sidi A, Dahleen L, Gaspardone A. Coronary vasospasm during anesthesia induction: Awareness, recognition, possible mechanisms, anesthetic factors, and treatment. J Clin Anesth 2008; 20: 64-69.
91. Soto E, Duvernoy W, David S, Small D, Nair M. Coronary artery spasm induced by anesthesia: A case report and review of the literature. Clin Cardiol 1990; 13: 59-61.
92. Himuro H, Aono K, Honda T, Nakajima T, Ohara G. A case of coronary artery spasm during oral surgery under general anesthesia. Anesth Pain Control Dent 1992; 4: 215-218.
93. Fradley MG, Barrett CD, Clark JR, Francis SA. Ventricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicity. Tex Heart Inst J 2013; 40: 472-476.
94. Sorrentino MF, Kim J, Foderaro AE, Truesdell AG. 5-fluorouracil induced cardiotoxicity: Review of the literature. Cardiol J 2012; 19: 453-458.
95. Maseri A, Lanza G. Fluorouracil-induced coronary artery spasm. Am J Med 2001; 111: 326-327.
96. Goldsmith YB, Roistacher N, Baum MS. Capecitabine-induced coronary vasospasm. J Clin Oncol 2008; 26: 3802-3804.
97. Tsiamis E, Synetos A, Stefanadis C. Capecitabine may induce coronary artery vasospasm. Hellenic J Cardiol 2012; 53: 320-323.
98. Arima Y, Oshima S, Noda K, Fukushima H, Taniguchi I, Nakamura S, et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol 2009; 54: 512-515.
99. Porto I, Leo A, Miele L, Pompili M, Landolfi R, Crea F. A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol 2010; 7: 476-480.
100. Takizawa A, Yasue H, Omote S, Nagao M, Hyon H, Nishida S, et al. Variant angina induced by alcohol ingestion. Am Heart J 1984; 107: 25-27.
101. Kashima T, Tanaka H, Arikawa K, Ariyama T. Variant angina induced by alcohol ingestion. Angiology 1982; 33: 137-139.
102. Oda H, Suzuki M, Oniki T, Kishi Y, Numano F. Alcohol and coronary spasm. Angiology 1994; 45: 187-197.
103. Tanabe Y, Yamazoe M, Igarashi Y, Tamura Y, Tsuchida K, Otsuka K, et al. Importance of coronary artery spasm in alcohol-related unexplained syncope. Jpn Heart J 1992; 33: 135-144.
104. Matsuguchi T, Araki H, Nakamura N, Etoh Y, Okamatsu S, Takeshita A, et al. Prevention of vasospastic angina by alcohol ingestion: Report of 2 cases. Angiology 1988; 39: 394-400.
105. Tanabe K, Nanke T, Nakazawa A, Miyake F, Mikawa T, Murayama M, et al. Inhibition of vasospastic angina by alcohol ingestion. Kokyu To Junkan 1990; 38: 919-923 (in Japanese).
106. Pijls N, van der Werf T. Prinzmetal’s angina associated with alcohol withdrawal. Cardiology 1988; 75: 226-229.
107. Mizuno Y, Harada E, Morita S, Kinoshita K, Hayashida M, Shono M, et al. East asian variant of aldehyde dehydrogenase 2 is associated with coronary spastic angina: Possible roles of reactive aldehydes and implications of alcohol flushing syndrome. Circulation 2015; 131: 1665-1673.
108. Bertrand ME, LaBlanche JM, Thieuleux FA, Fourrier JL, Traisnel G, Asseman P. Comparative results of percutaneous transluminal coronary angioplasty in patients with dynamic versus fixed coronary stenosis. J Am Coll Cardiol 1986; 8: 504-508.
109. David P, Waters D, Scholl J, Crepeau J, Szlachcic J, Lesperance J, et al. Percutaneous transluminal coronary angioplasty in patients with variant angina. Circulation 1982; 66: 695-702.
110. Leisch F, Harringer W, Kerschner K, Hofmann R, Feirer G, Schutzenberger W. Importance of coronary spasm for recurrences following percutaneous transluminal coronary angioplasty (PTCA). Eur Heart J 1991; 12: 1029-1033.
111. Sueda S, Suzuki J, Watanabe K, Mineoi K, Kondou T, Yano K, et al. Comparative results of coronary intervention in patients with variant angina versus those with non-variant angina. Jpn Heart J 2001; 42: 657-667.
112. Tanabe Y, Itoh E, Suzuki K, Ito M, Hosaka Y, Nakagawa I, et al. Limited role of coronary angioplasty and stenting in coronary spastic angina with organic stenosis. J Am Coll Cardiol 2002; 39: 1120-1126.
113. Hastey CE, Erwin SW, Ramanathan KB. Ergonovine-induced coronary spasm refractory to intracoronary nitroglycerin but responsive to nitroprusside. Am Heart J 1984; 107: 778-781.
114. Babbitt D, Perry J, Forman M. Intracoronary verapamil for reversal of refractory coronary vasospasm during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1988; 12: 1377-1381.
115. Phaneuf DC, Waters DD, Dauwe F, Theroux P, Pelletier G, Mizgala HF. Refractory variant angina controlled with combined drug therapy in a patient with a single coronary artery. Cathet Cardiovasc Diagn 1980; 6: 413-421.
116. Maseri A. Variant angina. In: Ischemic heart disease. A rational basis for clinical practise and clinical research. New York: Churchill Livingstone; 1995: 559-588.
117. Frenneaux M, Kaski JC, Brown M, Maseri A. Refractory variant angina relieved by guanethidine and clonidine. Am J Cardiol 1988; 62: 832-833.
118. Takagi S, Goto Y, Hirose E, Terashima M, Sakuragi S, Suzuki S, et al. Successful treatment of refractory vasospastic angina with corticosteroids: Coronary arterial hyperactivity caused by local inflammation? Circ J 2004; 68: 17-22.
119. Dominguez Franco AJ, Gomez Doblas JJ, Garcia Pinilla JM, Hernandez Garcia JM, Jimenez Navarro M, Alonso Briales JH, et al. Treatment of refractory vasoespastic angina with corticosteroids: A case report. Int J Cardiol 2007; 118: e51-e53, doi:10.1016/j.ijcard.2006.12.058.
120. Abbate A, Hamza M, Cassano AD, Melchior R, Roberts C, Grizzard J, et al. Sympathectomy as a treatment for refractory coronary artery spasm. Int J Cardiol 2012; 161: 7-9.
121. Chu G, Zhang G, Zhang Z, Liu S, Wen Q, Sun B. Clinical outcome of coronary stenting in patients with variant angina refractory to medical treatment: A consecutive single-center analysis. Med Princ Pract 2013; 22: 583-587.
122. Gaspardone A, Tomai F, Versaci F, Ghini AS, Polisca P, Crea F, et al. Coronary artery stent placement in patients with variant angina refractory to medical treatment. Am J Cardiol 1999; 84: 96-98, A98.
123. Jeong MH, Park JC, Rhew JY, Kang KT, Lee SH, Cho JH, et al. Successful management of intractable coronary spasm with a coronary stent. Jpn Circ J 2000; 64: 897-900.
124. Khatri S, Webb JG, Carere RG, Dodek A. Stenting for coronary artery spasm. Catheter Cardiovasc Interv 2002; 56: 16-20.
125. Kultursay H, Can L, Payzin S, Turkoglu C, Altintig A, Akin M, et al. A rare indication for stenting: Persistent coronary artery spasm. Heart Vessels 1996; 11: 165-168.
126. Lopez J, Angelini P, Leachman D, Lufschanowski R. Gianturco- Roubin stent placement for variant angina refractory to medical treatment. Cathet Cardiovasc Diagn 1994; 33: 161-165.
127. Serrador A, Roman JA, Duran JM, Gimeno F, Vega JL, Fernandez- Aviles F. Successful treatment of vasospastic angina with a coronary stent. J Invasive Cardiol 2000; 12: 586-588.
128. Sugimoto A, Morino Y, Ikari Y. Stent implantation for diffuse and multiple coronary spasm in a patient with variant angina refractory to optimal medical therapy. J Invasive Cardiol 2007; 19: 320-323.
129. Clark D, Quint R, Mitchell R, Dugell W. Coronary artery spasm: Medical manangement, surgical denervation and autotransplantation. J Thorac Cardiovasc Surg 1977; 73: 332-339.
130. Bertrand M, Lablanche J, Tilmant P, Thieuleux F, Ducloux G, Godin J, et al. Treatment of a severe coronary artery spasm, refractory to complete denervation of the heart (autotransplantation). Arch Mal Coeur Vaiss 1982; 75: 717-723 (in French).
131. Ong P, Aziz A, Hansen HS, Prescott E, Athanasiadis A, Sechtem U. Structural and functional coronary artery abnormalities in patients with vasospastic angina pectoris. Circ J 2015; 79: 1431-1438.
132. Shimokawa H. Cellular and molecular mechanisms of coronary artery spasm: Lessons from animal models. Jpn Circ J 2000; 64: 1-12.
133. Sueda S, Kohno H, Fukuda H, Watanabe K, Ochi N, Kawada H, et al. Limitations of medical therapy in patients with pure coronary spastic angina. Chest 2003; 123: 380-386.